Dr. Ian Mcdonald Joins SBI as Vice President
of Drug Discovery
Business Editors & Health/Medical Writers
BIOWIRE2K
SAN DIEGO--(BW HealthWire)--Jan. 4, 2001--Privately-held Structural Bioinformatics Inc.
(SBI) today announced that Dr. Ian McDonald has joined the Executive Management Team as its
Vice President of Drug Discovery.
Dr. McDonald will be responsible for all aspects of SBI's drug discovery efforts.
Immediately prior to joining SBI, Dr. McDonald was Senior Director of Chemistry at Merck
Research Laboratories, which acquired SIBIA Neurosciences in 1999, where he served as Vice
President from 1994 and Director of Chemistry since 1993. He received his B.S. and Ph.D. degrees
from the School of Chemistry, the University of Western Australia, and completed his postdoctoral
studies at the Organic Chemistry Institute of the University of Zurich. He has held senior positions at
the State Health Laboratories in Perth, Australia; at the Australian National University; the Centre de
Recherche Merrell International, Strasbourg, France; and Marion Merrell Dow, Cincinnati, Ohio. Dr.
McDonald has published about 80 peer-reviewed papers and book chapters, and currently is
Editor-in-Chief of Current Drug Targets - CNS and Neurological Diseases, which will debut in 2002.
He is also an inventor on 32 U.S. issued patents.
"Over the past few years, SBI has consistently demonstrated its unique ability to efficiently generate
initial hits from in silico screening of virtual libraries against modeled protein structures," said Dr. Ian
McDonald. "I am pleased to join SBI to expand its leadership position in drug discovery as we
expand our wet lab capabilities to advance these novel hits towards clinical validation."
"Dr. McDonald brings a unique and proven set of scientific and management skills necessary for the
continued growth and expansion of our drug discovery efforts," said Dr. Edward T. Maggio,
Chairman, President and Chief Executive Officer. "I am pleased that Dr. McDonald has joined SBI's
Management Team. His background and industry experience will enhance our drug discovery
capabilities."
About Structural Bioinformatics Inc.
SBI is a world leader in computational proteomics -- the large-scale generation and use of protein
structure and protein structural information. The company has developed advanced technologies to
generate highly refined 3-dimensional structural models of proteins from primary genetic information
and commercializes these technologies through its structural database products and through drug
discovery collaborations with leading pharmaceutical companies. SBI has offices and research
facilities in San Diego; Cambridge, Mass. and H0rsholm, Denmark. More information about SBI can
be found on the company's Web site at: strubix.com.
--30--ts/sd*
CONTACT: Structural Bioinformatics Inc.
Public Relations Contact:
Alicia Althoff, 858/675-2400 ext. 119
alicia@strubix.com |
